{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T19:28:08Z","timestamp":1782156488534,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.mcna.2023.04.005","type":"journal-article","created":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T06:53:31Z","timestamp":1685861611000},"page":"829-844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cold Hands or Feet"],"prefix":"10.1016","volume":"107","author":[{"given":"Daniella","family":"Kadian-Dodov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2023.04.005_bib1","unstructured":"Raynaud M. De l\u2019asphyxie locale et de la gangr\u00e8ne sym\u00e9trique des extr\u00e9mit\u00e9s. 1862."},{"issue":"8","key":"10.1016\/j.mcna.2023.04.005_bib2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrrheum.2012.96","article-title":"The pathogenesis, diagnosis and treatment of Raynaud phenomenon","volume":"8","author":"Herrick","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.mcna.2023.04.005_bib3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nrrheum.2014.195","article-title":"A\u00a0vascular mechanistic approach to understanding Raynaud phenomenon","volume":"11","author":"Flavahan","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.mcna.2023.04.005_bib4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1191\/1358863x05vm639ra","article-title":"Mechanisms of Raynaud's disease","volume":"10","author":"Cooke","year":"2005","journal-title":"Vasc Med"},{"issue":"1","key":"10.1016\/j.mcna.2023.04.005_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/1358863X20983455","article-title":"Raynaud's phenomenon and related vasospastic disorders","volume":"26","author":"Choi","year":"2021","journal-title":"Vasc Med"},{"issue":"18","key":"10.1016\/j.mcna.2023.04.005_bib6","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1001\/jama.1932.02740700012003","article-title":"RAYNAUD'S DISEASE: A CLINICAL STUDY OF ONE HUNDRED AND FORTY-SEVEN CASES","volume":"99","author":"Allen","year":"1932","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2023.04.005_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.01.020","article-title":"International consensus criteria for the diagnosis of Raynaud's phenomenon","volume":"48-49","author":"Maverakis","year":"2014","journal-title":"J\u00a0Autoimmun"},{"issue":"1","key":"10.1016\/j.mcna.2023.04.005_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s41927-022-00272-0","article-title":"Incidence, remission, and persistence of Raynaud's phenomenon in the general population of northern Sweden: a prospective study","volume":"6","author":"Stjernbrandt","year":"2022","journal-title":"BMC Rheumatol"},{"issue":"4","key":"10.1016\/j.mcna.2023.04.005_bib9","first-page":"419","article-title":"[Exposure to cold and the symptoms thereof]","volume":"121","author":"Rytkonen","year":"2005","journal-title":"Duodecim"},{"issue":"6752","key":"10.1016\/j.mcna.2023.04.005_bib10","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/bmj.301.6752.590","article-title":"Prevalence of symptoms of Raynaud's phenomenon in general practice","volume":"301","author":"Silman","year":"1990","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.mcna.2023.04.005_bib11","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/art.20988","article-title":"The incidence and natural history of Raynaud's phenomenon in the community","volume":"52","author":"Suter","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.mcna.2023.04.005_bib12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archinte.158.6.595","article-title":"Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases","volume":"158","author":"Spencer-Green","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mcna.2023.04.005_bib13","series-title":"Vascular medicine: a Companion to Braunwald\u2019s heart disease","first-page":"587","article-title":"Raynaud\u2019s Phenomenon","author":"Creager","year":"2013"},{"issue":"3","key":"10.1016\/j.mcna.2023.04.005_bib14","doi-asserted-by":"crossref","first-page":"e006389","DOI":"10.1136\/bmjopen-2014-006389","article-title":"Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies","volume":"5","author":"Garner","year":"2015","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.mcna.2023.04.005_bib15","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/archinte.1984.00350160096017","article-title":"Prevalence of Raynaud's phenomenon in patients with migraine","volume":"144","author":"Zahavi","year":"1984","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.mcna.2023.04.005_bib16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/1358863X11398519","article-title":"Acrocyanosis: the Flying Dutchman","volume":"16","author":"Kurklinsky","year":"2011","journal-title":"Vasc Med"},{"key":"10.1016\/j.mcna.2023.04.005_bib17","series-title":"Peripheral vascular diseases","first-page":"607","article-title":"Vascular Diseases Related to Extremes in Environmental Temperature","author":"Olin","year":"1996"},{"issue":"1","key":"10.1016\/j.mcna.2023.04.005_bib18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.1981.01650010032019","article-title":"A\u00a0distinctive variant of pernio. Clinical and histopathologic study of nine cases","volume":"117","author":"Herman","year":"1981","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2023.04.005_bib19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2020.05.109","article-title":"Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries","volume":"83","author":"Freeman","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"26","key":"10.1016\/j.mcna.2023.04.005_bib20","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1056\/NEJMicm1610146","article-title":"Achenbach's Syndrome","volume":"376","author":"Yamamoto","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2023.04.005_bib21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/pm\/pnac046","article-title":"Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th Edition","volume":"23","author":"Harden","year":"2022","journal-title":"Pain Med"},{"issue":"5","key":"10.1016\/j.mcna.2023.04.005_bib22","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1055\/s-0039-1688977","article-title":"Small Fiber Neuropathy","volume":"39","author":"Zhou","year":"2019","journal-title":"Semin Neurol"},{"issue":"4","key":"10.1016\/j.mcna.2023.04.005_bib23","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3899\/jrheum.091117","article-title":"Thumb involvement in Raynaud's phenomenon as an indicator of underlying connective tissue disease","volume":"37","author":"Chikura","year":"2010","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.mcna.2023.04.005_bib24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bcp.12912","article-title":"Drug-induced Raynaud's phenomenon: beyond beta-adrenoceptor blockers","volume":"82","author":"Khouri","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.mcna.2023.04.005_bib25","doi-asserted-by":"crossref","first-page":"102458","DOI":"10.1016\/j.autrev.2020.102458","article-title":"Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis","volume":"19","author":"Smith","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.mcna.2023.04.005_bib26","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1002\/art.27543","article-title":"Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis","volume":"62","author":"Herrick","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2023.04.005_bib27","series-title":"Strandness\u2019s Duplex Scanning in vascular disorders","first-page":"172","article-title":"Noninvasive Diagnosis of Upper Extremity Arterial Disease","author":"Moneta","year":"2015"},{"issue":"1","key":"10.1016\/j.mcna.2023.04.005_bib28","first-page":"11","article-title":"The diagnosis and treatment of Raynaud's phenomenon","volume":"77","author":"Porter","year":"1975","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.mcna.2023.04.005_bib29","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0025-7125(16)30623-X","article-title":"Raynaud's phenomenon and disease","volume":"73","author":"Cardelli","year":"1989","journal-title":"Med Clin North Am"},{"issue":"12","key":"10.1016\/j.mcna.2023.04.005_bib30","first-page":"CD000467","article-title":"Calcium channel blockers for primary and secondary Raynaud's phenomenon","volume":"12","author":"Rirash","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.mcna.2023.04.005_bib31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF00610065","article-title":"Prazosin treatment of primary Raynaud's phenomenon","volume":"24","author":"Nielsen","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.mcna.2023.04.005_bib32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/clpt.1986.166","article-title":"Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon","volume":"40","author":"Wollersheim","year":"1986","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.mcna.2023.04.005_bib33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/rheumatology\/keh390","article-title":"Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis","volume":"44","author":"Thompson","year":"2005","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.mcna.2023.04.005_bib34","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/j.1552-4604.1988.tb05720.x","article-title":"Dose-response study of prazosin in Raynaud's phenomenon: clinical effectiveness versus side effects","volume":"28","author":"Wollersheim","year":"1988","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.mcna.2023.04.005_bib35","first-page":"CD006687","article-title":"Vasodilators for primary Raynaud's phenomenon","volume":"5","author":"Su","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.mcna.2023.04.005_bib36","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.mcna.2023.04.005_bib37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3899\/jrheum.181173","article-title":"Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis","volume":"47","author":"de Vries-Bouwstra","year":"2020","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.mcna.2023.04.005_bib38","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acr.22018","article-title":"Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis","volume":"65","author":"Tingey","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"10","key":"10.1016\/j.mcna.2023.04.005_bib39","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","article-title":"Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials","volume":"72","author":"Roustit","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.mcna.2023.04.005_bib40","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","article-title":"Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study","volume":"75","author":"Hachulla","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.mcna.2023.04.005_bib41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.mcna.2023.04.005_bib42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial","volume":"70","author":"Matucci-Cerinic","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.mcna.2023.04.005_bib43","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.mcna.2023.04.005_bib44","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.mcna.2023.04.005_bib45","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2018.01.043","article-title":"A\u00a0systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud's phenomenon","volume":"78","author":"Curtiss","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.mcna.2023.04.005_bib46","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00296-018-4119-9","article-title":"Use of nitroglycerin ointment to treat primary and secondary Raynaud's phenomenon: a systematic literature review","volume":"38","author":"Qiu","year":"2018","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.mcna.2023.04.005_bib47","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaad.2017.08.018","article-title":"Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: A randomized, double-blind, controlled pilot study","volume":"78","author":"Wortsman","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.mcna.2023.04.005_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11110594","article-title":"Development of a UV-Stabilized Topical Formulation of Nifedipine for the Treatment of Raynaud Phenomenon and Chilblains","volume":"11","author":"Wasan","year":"2019","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.mcna.2023.04.005_bib49","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s10067-020-04966-z","article-title":"Possible benefit of tadalafil cream for the treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis","volume":"39","author":"Fernandez-Codina","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.mcna.2023.04.005_bib50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0167-5273(88)90012-5","article-title":"Effect of intermittent venous occlusion on transcutaneous oxygen tension in lower limbs with severe arterial occlusive disease","volume":"21","author":"Rooke","year":"1988","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.mcna.2023.04.005_bib51","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/000331970505600409","article-title":"Use of intermittent pneumatic compression for treatment of upper extremity vascular ulcers","volume":"56","author":"Pfizenmaier","year":"2005","journal-title":"Angiology"},{"issue":"3","key":"10.1016\/j.mcna.2023.04.005_bib52","doi-asserted-by":"crossref","first-page":"101684","DOI":"10.1016\/j.berh.2021.101684","article-title":"Botulinum toxin in the management of primary and secondary Raynaud's phenomenon","volume":"35","author":"Ennis","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.mcna.2023.04.005_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.hcl.2013.09.006","article-title":"Minimally invasive treatment of Raynaud phenomenon: the role of botulinum type A","volume":"30","author":"Neumeister","year":"2014","journal-title":"Hand Clin"},{"issue":"1","key":"10.1016\/j.mcna.2023.04.005_bib54","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.hcl.2014.09.003","article-title":"The role of botulinum toxin in vasospastic disorders of the hand","volume":"31","author":"Neumeister","year":"2015","journal-title":"Hand Clin"},{"issue":"1","key":"10.1016\/j.mcna.2023.04.005_bib55","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jvs.2011.01.069","article-title":"Thoracic sympathectomy for digital ischemia: a summary of evidence","volume":"54","author":"Coveliers","year":"2011","journal-title":"J\u00a0Vasc Surg"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712523000603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712523000603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:46:53Z","timestamp":1758419213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712523000603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0025712523000603"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2023.04.005","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cold Hands or Feet","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2023.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}